Harpoon Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:HARP Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
12 Mar 24	SellUS$31,629,758	GAMCO Investors, Inc.	Company	1,375,331	US$23.00
12 Mar 24	SellUS$9,016,000	Gabelli & Company Investment Advisers, Inc.	Company	392,000	US$23.00
06 Mar 24	BuyUS$6,731,487	GAMCO Investors, Inc.	Company	293,200	US$22.98
26 Feb 24	BuyUS$0	GAMCO Investors, Inc.	Company	1,087,281	US$22.95
22 Feb 24	BuyUS$0	Gabelli & Company Investment Advisers, Inc.	Company	396,850	US$22.94
21 Feb 24	SellUS$116,495	GAMCO Investors, Inc.	Company	5,150	US$22.62
21 Feb 24	SellUS$109,709	Gabelli & Company Investment Advisers, Inc.	Company	4,850	US$22.62

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of HARP?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	0	0%
Individual Insiders	57,790	0.27%
General Public	1,300,974	6.08%
Public Companies	2,399,824	11.2%
Hedge Funds	3,849,060	18%
VC/PE Firms	4,659,169	21.8%
Institutions	9,130,388	42.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 543.9%.

Top Shareholders

Top 25 shareholders own 92.24% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
11.2%	Merck & Co., Inc.	2,399,824	US$55.2m	0%	no data
11%	Cormorant Asset Management, LP	2,349,060	US$54.1m	4,250%	2.27%
8.69%	New Leaf Venture Partners, LLC	1,859,169	US$42.8m	0%	26.26%
7.01%	RA Capital Management, L.P.	1,500,000	US$34.5m	0%	0.45%
7.01%	Commodore Capital LP	1,500,000	US$34.5m	0%	2.21%
6.97%	Franklin Resources, Inc.	1,492,368	US$34.3m	1,030%	0.01%
6.08%	Artal Group S.A.	1,300,000	US$29.9m	-31.7%	0.81%
5.06%	GAMCO Investors, Inc.	1,082,131	US$24.9m	0%	0.1%
4.11%	The Vanguard Group, Inc.	880,017	US$20.2m	676%	no data
3.84%	Soleus Capital Management, L.P.	820,638	US$18.9m	0%	1.77%
3.81%	Blackstone Alternative Asset Management L.P.	815,000	US$18.8m	0%	10.38%
3.2%	Citadel Advisors LLC	685,000	US$15.8m	1,300%	0.02%
2%	Ally Bridge Group	428,400	US$9.9m	0%	2.85%
1.83%	Gabelli & Company Investment Advisers, Inc.	392,000	US$9.0m	0%	1.87%
1.49%	BioImpact Capital LLC	319,670	US$7.4m	0%	1.3%
1.46%	MPM Asset Management, L.L.C.	313,136	US$7.2m	0%	2.57%
1.4%	Adage Capital Management, L.P.	300,000	US$6.9m	0%	0.01%
1.39%	Sio Capital Management, LLC	297,936	US$6.9m	77.3%	2.48%
1.17%	BlackRock, Inc.	249,834	US$5.7m	576%	no data
1.07%	Lion Point Capital, LP	228,900	US$5.3m	178%	4.42%
1.02%	Arix Bioscience plc	219,093	US$5.0m	0%	27.04%
0.7%	Geode Capital Management, LLC	149,262	US$3.4m	499%	no data
0.25%	Water Island Capital, LLC	54,472	US$1.3m	0%	0.14%
0.24%	Kennedy Capital Management LLC	52,160	US$1.2m	-1.56%	0.03%
0.23%	Goldman Sachs Group, Investment Banking and Securities Investments	48,948	US$1.1m	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/03/11 14:21
End of Day Share Price	2024/03/11 00:00
Earnings	2023/09/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Harpoon Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Arlinda Lee	Canaccord Genuity
Jennifer Kim	Cantor Fitzgerald & Co.